Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904734 · ClinicalTrials.gov registry record · Phase 2
Clomid in Men With Low Testosterone With and Without Prior Treatment
A Phase 2 study of Hypogonadism, Male, sponsored by Phoenix VA Health Care System.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01904734 is a Phase 2 study of Hypogonadism, Male that has completed, run by Phoenix VA Health Care System. The registered enrollment target is 42 participants, below the 109-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01904734, a Phase 2 study of Hypogonadism, Male, has completed, sponsored by Phoenix VA Health Care System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility that has been shown to improve male hormone secretion in some cases.
Conditions Studied
Interventions
- DRUG Clomiphene
Study Locations (1)
Arizona
- Phoenix VA Health Care System - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904734
The ClinicalTrials.gov registry entry for NCT01904734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (61% lower). The listed sponsor is Phoenix VA Health Care System, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Clomiphene is the first listed.
NCT01904734 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01904734 about?
NCT01904734 is a clinical study titled "Clomid in Men With Low Testosterone With and Without Prior Treatment". This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility ...
What is the current status of trial NCT01904734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-10. Estimated completion is 2018-10-31.
What conditions does trial NCT01904734 study?
This clinical trial studies the following conditions: Hypogonadism, Male.
What interventions are being tested in trial NCT01904734?
The interventions under investigation include: Clomiphene (DRUG).
Who is sponsoring clinical trial NCT01904734?
This trial is sponsored by Phoenix VA Health Care System, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01904734 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
Testosterone Treatment in Men with Chronic Kidney Disease
RECRUITING · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.